In conclusion, compared with traditional insulin pens, the use of needle-free syringes and enhanced management can effectively reduce the fasting blood glucose of patients with early-onset type 2 diabetes mellitus treated with premixed insulin. The gene discussed is INS; the disease is type 2 diabetes mellitus.